Short interest for Avalo Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Avalo Therapeutics's stock. Short interest data is updated every two weeks.

Avalo Therapeutics Stock (NASDAQ:AVTX), Short Interest Report

Avalo Therapeutics

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

pharma lab worker ai

Analyst Color

Biotech

Equities

News

Upgrades

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

ABBV

AVTX

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.

Avalo Therapeutics&#39; Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades

Penny Stocks

Small Cap

Intraday Update

Markets

ACON

ACOR

ADTX

ALLG

ASTS

AWIN

CIFR

CISS

CLSK

CXAI

DCFC

GCTS

GOEV

GRTS

GUTS

JZXN

LIFW

MSTR

MVST

ORGS

PPSI

PTPI

QDEL

SIGA

SNAX

TPET

VERV

VTSI

VVPR

XTIA

YTEN

Shares of  Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.

Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Pre-Market Outlook

DHAC

IMCC

SMXT

TCON

ZPTA

Shares of  VirTra, Inc. (NASDAQ: VTSI) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter results.

Why VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Avalo Therapeutics Inc

Avantium NV

NVAX

Novavax Exec Says Have Decided In Consultation With FDA To Seek Emergency Use Authorization For Updated Covid Vaccine Targeting JN.1 Variant; Reduced Workforce By 30% Compared To Q1 2023

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) with a Buy and maintains $26 price target.

Reiteration

PHAT

Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

Novavax Exec Says Intend To Have Covid Vaccine At Distribution Centers In The U.S. No Later Than Mid August; Intend To Have Covid Vaccine Ready For The Fall Season In Early September Pending FDA Approval; "Will Have Improved Retail Access For The Season" For Co's Covid Vaccine

Novavax Exec Says Now Anticipate Data Readouts For Both Novavax's Combination Covid-Flu Shot And Standalone Flu Vaccine In Mid 2025; Expect Royalties, Milestones From Deal With Sanofi To Exceed Value Of What Co's Own Efforts Might Have Yielded; Has Been Challenging For Co To Transition From Being An Innovator To Being A Commercial Business

AMC Networks Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>)&nbsp;reported a fiscal first-quarter 2024 revenue decline of 16.9% year over year to $596.46 million, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g38756320/amc-networks-inc-reports-first-quarter-2024-results" rel="noreferrer noopener">analyst consensus estimate of $602.60 million</a>.
The American entertainment company's adjusted EPS of $1.16 fell 55.7% year over year and missed the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $1.67</a>.&nbsp;The stock slid after the print.
Domestic Operations:&nbsp;Affiliate revenue decreased 14% due to&nbsp;basic&nbsp;subscriber declines. Advertising revenues decreased 13% Y/Y to $140 million due to anticipated linear ratings declines and a challenging ad market.&nbsp;
Content licensing revenues declined 40% to $62 million as the corresponding 2023 period included deliveries of&nbsp;AMC Studios-produced series&nbsp;Silo.
Despite these setbacks, AMC Networks reported that streaming subscribers increased by 2% to 11.5 million across its offerings, including AMC+, which added "<a target="_blank" href="https://www.benzinga.com/general/entertainment/24/03/37472003/the-walking-dead-to-the-rescue-again-could-zombie-stock-amc-networks-come-to-life-with-new-" rel="noreferrer noopener">The Walking Dead: The Ones Who Live</a>" starring Andrew Lincoln and Danai Gurira.&nbsp;This&nbsp;is compared&nbsp;to 11.2 million subscribers as of March 31, 2023.
The company returned to streaming subscriber growth in the third quarter of 2023 after two quarters of declines, the Hollywood Reporter&nbsp;<a target="_blank" href="https://www.hollywoodreporter.com/business/business-news/amc-networks-q1-earnings-advertising-streaming-walking-dead-1235895528/" rel="noreferrer noopener">reports</a>.
Streaming revenues of $145 million increased 3%, primarily driven by year-over-year streaming subscriber growth and price increases.
The consolidated adjusted operating income decreased 30.9% to $149.12 million, with free cash flow at $144.15 million.
The company, helmed by CEO Kristin Dolan, is tilting toward data-led audience targeting for ad buying as marketing dollars&nbsp;continue to&nbsp;shift from linear TV networks to streaming platforms.
AMC Networks stock lost close to 8% in the last 12 months.&nbsp;Investors can gain exposure to the stock via&nbsp;Invesco Leisure&nbsp;And Entertainment ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEJ#NYSE">PEJ</a>) and&nbsp;Schwab Strategic&nbsp;Trust Schwab Crypto Thematic ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STCE#NYSE">STCE</a>).
Price Action:&nbsp;AMCX shares are down 4.08% at $13.17 premarket at&nbsp;the last check Friday.

Earnings

Guidance

Tech

Media

AMCX

PowerShares ETF Leisure & Entertainment Port

STCE

AMC Networks Stock Slips: What's Behind the Sharp Revenue and EPS Decline?

Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) posted upbeat earnings for its first quarter, but <a href="https://www.benzinga.com/quote/AKAM/earnings">issued weak guidance</a>.
Akamai Technologies posted quarterly adjusted earnings of $1.64 per share, beating market estimates of $1.61 per share. The company's sales came in at $987.000 million, versus expectations of $989.261 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
&#8220;We are pleased with our continuing execution on our long-term strategy to drive revenue growth in our security and compute solutions,&#8221; said Dr. Tom Leighton, Akamai&#8217;s Chief Executive Officer. &#8220;Both solutions had a strong start to 2024 and collectively grew more than 20% year-over-year, representing almost two-thirds of total revenue. We&#8217;re particularly excited about our planned acquisition of Noname Security, which will enhance Akamai&#8217;s existing API Security solution and accelerate our ability to meet growing customer demand.&#8221;
Akamai said it sees second-quarter adjusted earnings of $1.51 to $1.56 per share, versus estimates of $1.63 per share. The company expects revenue of $967 million to $986 million, versus expectations of $1 billion.
The company said it sees FY24 adjusted EPS of $6.20 to $6.40 compared to market estimates of $6.73. It expects revenue of $3.95 billion to $4.02 billion, versus expectations of $4.08 billion, according to data from Benzinga Pro.
Akamai Technologies shares rose 0.3% to close at $102.46 on Thursday.
These analysts made changes to their price targets on Akamai Technologies following earnings announcement.
<ul>
<li>Baird cut the price target on Akamai Technologies from $135 to $120. Baird analyst William Power maintained an Outperform rating.</li>
<li>B of A Securities slashed the price target on Akamai Technologies from $145 to $125. B of A Securities analyst Madeline Brooks maintained a Buy rating.</li>
<li>Susquehanna lowered the price target on Akamai Technologies from $150 to $135. Susquehanna analyst Aaron Samuels maintained a Positive rating.</li>
</ul>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38757985/top-2-materials-stocks-that-could-blast-off-this-quarter">Top 2 Materials Stocks That Could Blast Off This Quarter</a>

AKAM

Akamai Technologies Analysts Cut Their Forecasts After Weak Forecast

WIIM

AEHL

Antelope Enterprise shares are trading lower after the company announced second half and full year 2023 financial results.

Keefe, Bruyette &amp; Woods analyst Bose George reiterates UWM Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) with a Market Perform and raises the price target from $6 to $7.

UWMC

Keefe, Bruyette & Woods Reiterates Market Perform on UWM Hldgs, Raises Price Target to $7

CRH plc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) shares are trading higher after it reported first-quarter FY24 results and&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38752604/crh-q1-2024-results" rel="noreferrer noopener">disclosed its&nbsp;share repurchase program</a>.
Revenue rose 2% Y/Y to $6.5 billion, while&nbsp;organic revenues increased 1% Y/Y, aided by early-season project activity and favorable weather in&nbsp;certain regions&nbsp;of North America, which were further supported by pricing progress and contributions from acquisitions.&nbsp;
By segment, revenue from Americas Materials Solutions&#8217;&nbsp;grew 16% Y/Y, Americas Building Solutions rose 2%, Europe Materials Solutions was down&nbsp;8%, and Europe Building Solutions declined&nbsp;10% Y/Y in the year.&nbsp;
Adjusted EBITDA rose 15% Y/Y to $445 million, aided by continued delivery of the integrated solutions strategy,&nbsp;strong&nbsp;commercial progress, ongoing cost control, and further operational efficiencies. Adjusted EBITDA margin expanded to 6.8% from 6.0% the prior year.&nbsp;
EPS stood at $0.16 (vs. loss per share of $(0.05)) due to positive operating performance and the gain on the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">divestiture of the Lime operations</a>.
CRH ended first-quarter FY24 with cash and equivalents of $3.3 billion and $3.8 billion of undrawn committed facilities available until May 2029.
Buyback: CRH repurchased shares worth $0.4 billion in the quarter and disclosed that it has completed the latest phase of its share buyback program of $0.3 billion.
CRH also disclosed that it&nbsp;inked an arrangement with&nbsp;HSBC Securities&nbsp;to repurchase an aggregate maximum consideration of up to $0.3 billion, which commenced today, May 10, 2024, and will&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38752689/crh-continues-share-buyback-program" rel="noreferrer noopener">end no later than August 7, 2024</a>.
Dividend: The Board declared a quarterly dividend per share of $0.35, payable&nbsp;on June 26, 2024, to shareholders of record as of May 24, 2024.
FY24 Outlook: CRH&nbsp;continues to expect&nbsp;EPS of $5.15-$5.45&nbsp;vs. consensus of $5.40 and adjusted&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">EBITDA of&nbsp;$6.55 billion-$6.85 billion</a>.
Overall,&nbsp;the company projects a favorable market and continued positive pricing momentum in 2024.
Price Action: CRH shares are up 4.36% at $83.81 premarket at the last check Friday.
Photo by Sirisak_baokaew via Shutterstock

Large Cap

Dividends

Buybacks

Why Is Construction Materials Company CRH Stock Up Premarket Friday?

Novartis Gets FDA Breakthrough Designation For Scemblix

TORO

Toro Q1 EPS $0.51 Up From $0.35 YoY, Total Vessel Revenues $7.00M Down From $31.15M YoY

Management

QTWO

Q2 Holdings Appoints CEO Matt Flake As Chairman; Succeeds R.H. Seale

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith reiterates Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) with a Outperform and raises the price target from $21 to $22.

HIPO

Keefe, Bruyette & Woods Reiterates Outperform on Hippo Holdings, Raises Price Target to $22

HYPR

Hyperfine Enters Agreements With Distributors In France, UK And Italy

Atlanta Federal Reserve President Raphael Bostic has indicated that a reduction in interest rates by the U.S. central bank is likely this year, though the timing and magnitude of such a move remain unclear.
What Happened: Bostic, in a recent interview with Reuters, stated that despite a first quarter where inflation seemed to hover above the Fed&#8217;s 2% target, he still sees room for a rate cut within the year.
He also mentioned that discussions with businesses in his U.S. Southeast Fed district point towards a probable deceleration in wage and job growth. Many companies reportedly feel their ability to control prices is waning following the swift price increases that resulted in 40-year inflation highs in 2022.
Despite April&#8217;s weaker-than-anticipated U.S. job growth, Bostic remains optimistic about further progress on inflation throughout the year, potentially setting the stage for the Fed to start easing monetary policy. However, he expects this process to be gradual.
See Also: <a href="https://www.benzinga.com/news/earnings/24/05/38727392/wall-street-stares-at-weaker-open-on-rate-anxiety-hopes-for-better-earnings-analyst-pencils-key-s-p?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">S&amp;P 500, Nasdaq To Open Lower Today: What&#8217;s Dragging Stock Futures?</a>
Why It Matters: This follows Federal Reserve Chairman<a href="https://www.benzinga.com/economics/macro-economic-events/24/05/38584705/federal-reserve-takes-cautious-stand-on-inflation-powell-signals-preference-for-r"> Jerome Powell&#8217;s cautious approach</a> to monetary policy, suggesting interest rates may hold steady longer than anticipated.
With inflation expected to return to 2% by late 2025 or early 2026, Bostic&#8217;s remarks hint at a careful strategy to prevent a sharp increase in unemployment. This comes as the Fed&#8217;s preferred inflation measure, the personal consumption expenditures price index, rose at a 2.7% annual rate in March. Furthermore, <a href="https://www.benzinga.com/news/24/05/38720656/feds-rate-cut-could-trigger-stock-market-melt-up-warns-investment-strategist">investment strategist Ed Yardeni warned</a> that the Fed&#8217;s potential monetary easing through interest rate cuts could trigger a surge in the stock market.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38690365/pro-bitcoin-president-javier-mileis-argentina-introduces-10-000-peso-notes-as-it-combats-h?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Pro-Bitcoin President Javier Milei&#8217;s Argentina Introduces 10,000-Peso Notes As It Combats Hyperinflation, Currency Collapse</a>
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Macro Economic Events

Economics

Atlanta Fed Chief Hints At Potential Interest Rate Cut This Year Amid Economic Uncertainties

In a significant development, Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) has announced plans to enhance production at its Valencia plant in Spain. The automaker aims to assemble 300,000 units of a new model annually starting in 2027.
What Happened: Spain&#8217;s Industry Ministry confirmed Ford&#8217;s decision to boost production at its Spanish plant, Reuters reported on Friday. The automaker had previously hinted at this move in March when it disclosed its consideration for the production of a new sports utility vehicle (SUV) at the Valencia facility.
The Industry Ministry praised the move, stating, &#8220;It is a model that will guarantee the workload for this factory and prepares it for the future.&#8221; 
The Valencia plant, currently employing 4,800 people, is where Ford assembles its Kuga SUV. The production of other models at this plant has been reduced in recent years.
See Also: <a href="https://www.benzinga.com/news/24/05/38722260/tesla-drivers-rejoice-elon-musk-says-fsd-nag-on-steering-wheel-is-finally-fixed-and-rolling-out-in-n?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla Drivers Rejoice: Elon Musk Says FSD Nag On Steering Wheel Is Finally Fixed And Rolling Out In Next</a>
Why It Matters: This strategic move by Ford is expected to strengthen the workload and future readiness of the Valencia plant. It also signifies Ford&#8217;s commitment to expanding its SUV line-up and its operations in Spain. In June 2022, Ford had <a href="https://www.benzinga.com/news/22/06/27811518/ford-to-produce-next-wave-of-electric-vehicles-in-spain">announced its intention to manufacture</a> its next generation of electric vehicles at its factory in Valencia, Spain.
However, in April, Ford <a href="https://www.benzinga.com/news/24/04/38163689/fords-delay-of-its-all-electric-suv-is-not-the-result-of-gone-ev-euphoria-but-part-of-a-wise-strateg">decided to delay the production</a> of an all-electric SUV and pickup truck to introduce hybrids across its North American lineup by the end of the decade. This decision came in response to the demand slowdown and the financial challenges faced by the company in its EV venture.
Price Action: On Thursday, Ford&#8217;s stock closed 0.16%, lower at $12.13, a slight increase of 0.05 from the previous close. The company&#8217;s first-quarter earnings for 2024 surpassed estimates with an EPS of 0.49 against an estimated 0.42.
Read Next: <a href="https://www.benzinga.com/news/24/05/38727916/whats-with-thousands-of-teslas-piling-up-at-a-german-airfield-satellite-images-hint-at-intense-inven?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">What&#8217;s With Thousands Of Teslas Piling Up At A German Airfield? Satellite Images Hint At Intense Inventor</a>
Photo via Wikimedia Commons
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Ford To Increase Production At Valencia Plant With New Model

SANW

S&W Seed Launches Double Team Forage Sorghum

Watts Water Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTS#NYSE">WTS</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $212.0, a high estimate of $225.00, and a low estimate of $206.00. Marking an increase of 4.95%, the current average surpasses the previous average price target of $202.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1715346059_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Watts Water Technologies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$209.00</td>
<td>$206.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$208.00</td>
<td>$191.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$206.00</td>
<td>$199.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Watts Water Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Watts Water Technologies compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Watts Water Technologies's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WTS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Watts Water Technologies analyst ratings.</a>
<h2>Get to Know Watts Water Technologies Better</h2>
Watts Water Technologies Inc is a U.S.-based company that provides safety, energy efficiency, and water conservation products. Its product portfolio includes residential and commercial flow control products, which are sold for plumbing and hot water applications; HVAC and gas products, including commercial boilers, water heaters, heating solutions, and heating systems; drainage and water reuse products, including drainage products and engineered rainwater-harvesting solutions; and water quality products, including point-of-use and point-of-entry water filtration, conditioning, and scale prevention systems. The company generates the majority of its revenue from markets in the Americas and in Europe, the Middle East, and Africa.
<h3>A Deep Dive into Watts Water Technologies's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Watts Water Technologies's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 9.09%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Watts Water Technologies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 10.17%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Watts Water Technologies's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.76%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Watts Water Technologies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.57%, the company showcases efficient use of assets and strong financial health.
Debt Management: Watts Water Technologies's debt-to-equity ratio is below the industry average at 0.2, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Watts Water Technologies

During the last three months, 6 analysts shared their evaluations of CS Disco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAW#NYSE">LAW</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $12.08, a high estimate of $15.00, and a low estimate of $7.50. This upward trend is evident, with the current average reflecting a 12.37% increase from the previous average price target of $10.75.
<img src="https://www.benzinga.com/files/images/story/2024/1715346049_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive CS Disco. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Sterling Auty</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$9.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$7.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CS Disco. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CS Disco compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of CS Disco's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CS Disco's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LAW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CS Disco analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into CS Disco's Background</h2>
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
<h3>CS Disco: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, CS Disco showcased positive performance, achieving a revenue growth rate of 9.85% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: CS Disco's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -16.34%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CS Disco's ROE stands out, surpassing industry averages. With an impressive ROE of -2.91%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): CS Disco's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.53%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.05, CS Disco adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 6 Takes On CS Disco

In the latest quarter, 7 analysts provided ratings for PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for PAR Technology, presenting an average target of $54.29, a high estimate of $65.00, and a low estimate of $42.00. Witnessing a positive shift, the current average has risen by 14.71% from the previous average price target of $47.33.
<img src="https://www.benzinga.com/files/images/story/2024/1715346041_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of PAR Technology by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$53.00</td>
<td>-</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$53.00</td>
<td>-</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>George Sutton</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ishfaque Faruk</td>
<td>Sidoti &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$61.00</td>
<td>-</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$53.00</td>
<td>-</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to PAR Technology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PAR Technology compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of PAR Technology's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into PAR Technology's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PAR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PAR Technology analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind PAR Technology</h2>
PAR Technology Corp together with its subsidiaries provides management technology solutions including software, hardware, and related services, integral to the point-of-sale infrastructure and task management, information gathering, assimilation, and communication services. It has two segments. The restaurant/ Retail segment provides point-of-sale and management technology solutions such as hardware, software, and integrated technical solutions to the restaurant and retail industries. The government segment provides intelligence, surveillance, and reconnaissance solutions and mission systems support. The company derives the majority of its revenues from the Restaurant/ Retail segment.
<h3>PAR Technology: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: PAR Technology's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 10.3%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: PAR Technology's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -17.3%, the company may face hurdles in effective cost management.
Return on Equity (ROE): PAR Technology's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -5.6%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): PAR Technology's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.31%, the company may face hurdles in achieving optimal financial performance.
Debt Management: PAR Technology's debt-to-equity ratio surpasses industry norms, standing at 1.15. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

7 Analysts Assess PAR Technology: What You Need To Know

KOD, ALLG and SST among mid-day movers

These Healthcare stocks are trading higher:-Avalo Therapeutics Inc (AVTX) stock is trading at $22.82, a gain of $18.07, or 370.53%, on high volume.  Avalo Therapeutics Inc gets a Sentiment Score of Bullish from InvestorsObserver and receives an average analyst recommendation of Buy with a price target of $178.57. Avalo The

Healthcare Stocks Moving Up and Down Thursday: AVTX, XLO, NXL, BDRX, KOD, AKBA, VINC, TOI

Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M

Avalo Therapeutics Inc (AVTX) is down -20.92%% today. AVTX has an Overall Score of 100. Find out what this means to you and get the rest of the rankings on AVTX!See Full AVTX ReportAVTX stock closed at $21.75 and is down -$4.55 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volum

Premarket Mover: Avalo Therapeutics Inc (AVTX) Down 20.92%

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning!



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>MediaCo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdia-stock-quote/">MDIA</a>) stock is rocketing more than 41% alongside heavy pre-market trading.</li>



<li>Mountain Crest Acquisition Corp. IV &ndash; Rights (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcafr-stock-quote/">MCAFR</a>) shares are soaring over 37% after its combination with CH Auto Technology.</li>



<li>Xilio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/xlo-stock-quote/">XLO</a>) stock is surging more than 34% following a <a href="https://www.nasdaq.com/press-release/xilio-therapeutics-announces-%2411.3-million-private-placement-equity-financing-2024-03">recent private placement</a>.</li>



<li>U Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/ucar-stock-quote/">UCAR</a>) shares are gaining over 33% as it prepares for a <a href="https://www.nasdaq.com/press-release/u-power-limited-announces-1-for-100-share-consolidation-2024-03-29">reverse stock split this week</a>.</li>



<li>Doma (NYSE:<a href="https://investorplace.com/stock-quotes/doma-stock-quote/">DOMA</a>) stock is increasing more than 33% after <a href="https://www.nasdaq.com/press-release/doma-enters-into-agreement-to-go-private-at-price-of-%246.29-per-share-in-cash-plans-to">announcing plans to go private</a>.</li>



<li>Jaguar Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/jagx-stock-quote/">JAGX</a>) shares are rising over 27% ahead of its <a href="https://www.defenseworld.net/2024/03/30/jaguar-health-jagx-scheduled-to-post-earnings-on-monday.html">earnings report today</a>.</li>



<li>Torrid (NYSE:<a href="https://investorplace.com/stock-quotes/curv-stock-quote/">CURV</a>) stock is climbing more than 21% alongside its <a href="https://www.nasdaq.com/press-release/torrid-reports-fourth-quarter-and-fiscal-2023-results-and-initiates-fiscal-2024">Q4 2023 earnings report</a>.</li>



<li>Qilian (NASDAQ:<a href="https://investorplace.com/stock-quotes/qli-stock-quote/">QLI</a>) shares are heading over 21% higher on Monday morning.</li>



<li>Project Energy Reimagined (NASDAQ:<a href="https://investorplace.com/stock-quotes/pegr-stock-quote/">PEGR</a>) stock is jumping more than 15% this morning.</li>



<li>Iterum Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/itrm-stock-quote/">ITRM</a>) shares are up over 14% with the release of its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318200256&amp;type=PDF&amp;symbol=ITRM&amp;cdn=84f4de18c33af3dabfe15c62944102cf&amp;companyName=Iterum+Therapeutics+plc&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-03-29">latest earnings report</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Mountain Crest Acquisition Corp (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcaf-stock-quote/">MCAF</a>) stock is plummeting more than 58% alongside its CH Auto Technology merger.</li>



<li>X3 Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtkg-stock-quote/">XTKG</a>) shares are diving close to 32% despite <a href="https://www.nasdaq.com/press-release/x3-holdings-strikes-major-partnership-deal-poised-to-transform-semiconductor-supply-0">announcing a new partnership</a>.</li>



<li>Endra Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ndra-stock-quote/">NDRA</a>) stock is tumbling over 27% after releasing its <a href="https://www.nasdaq.com/press-release/endra-life-sciences-reports-fourth-quarter-and-full-year-2023-financial-results-and">Q4 earnings report</a>.</li>



<li>Sintx Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sint-stock-quote/">SINT</a>) shares are taking a more than 25% beating after revealing a <a href="https://fox40.com/business/press-releases/globenewswire/9081720/sintx-technologies-announces-proposed-public-offering-of-common-stock">proposed public offering</a>.</li>



<li>Avalo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/avtx-stock-quote/">AVTX</a>) stock is falling over 17% alongside its <a href="https://www.globenewswire.com/news-release/2024/03/29/2854834/0/en/Avalo-Reports-2023-Financial-Results-and-Provides-Business-Updates.html">fiscal 2023 earnings results</a>.</li>



<li>Binah Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/bcg-stock-quote/">BCG</a>) shares are decreasing more than 15% after <a href="https://investorplace.com/2024/03/why-is-binah-capital-bcg-stock-up-93-today/">recently going public</a>.</li>



<li>Vivos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvos-stock-quote/">VVOS</a>) stock is dropping over 15% after <a href="https://finance.yahoo.com/news/vivos-therapeutics-full-2023-earnings-123004258.html">missing earnings estimates</a>.</li>



<li>Nuvve (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvve-stock-quote/">NVVE</a>) shares are slipping more than 14% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318199610&amp;type=PDF&amp;symbol=NVVE&amp;cdn=a217b6757d315c4bd6039ed7032d2928&amp;companyName=Nuvve+Holding+Corp.&amp;formType=10-K&amp;formDescription=Annual+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-03-29">following a business update</a>.</li>



<li>3M (NYSE:<a href="https://investorplace.com/stock-quotes/mmm-stock-quote/">MMM</a>) stock is dipping over 14% after <a href="https://finance.yahoo.com/news/3m-completes-spin-off-solventum-103000495.html">completing a spinoff</a>.</li>



<li>Steakholder Foods (NASDAQ:<a href="https://investorplace.com/stock-quotes/stkh-stock-quote/">STKH</a>) shares close out our pre-market stock movers down more than 14% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-april-1st/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

MSTR, BIOR and ARBK among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to check out all of the biggest pre-market stock movers worth watching on Tuesday morning!



Moving stocks this morning are merger agreements, earnings reports, and a major spinoff worth checking out.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>XTI Aerospace (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtia-stock-quote/">XTIA</a>) stock is rocketing more than 94% alongside heavy pre-market trading.</li>



<li>Kidpik (NASDAQ:<a href="https://investorplace.com/stock-quotes/pik-stock-quote/">PIK</a>) shares are soaring over 65% after <a href="https://www.businesswire.com/news/home/20240401494590/en/Kidpik-and-Nina-Footwear-Announce-Entry-Into-Definitive-Merger-Agreement">announcing a merger agreement</a>.</li>



<li>MSP Recovery (NASDAQ:<a href="https://investorplace.com/stock-quotes/lifw-stock-quote/">LIFW</a>) stock is surging more than 51% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318207498&amp;type=PDF&amp;symbol=LIFW&amp;cdn=d7d2eb0036ce9fef1e4f01d2811ba3c3&amp;companyName=MSP+Recovery+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-01">amending a Master Transaction Agreement</a>.</li>



<li>Gaxos.AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/gxai-stock-quote/">GXAI</a>) shares are gaining over 42% on Tuesday morning.</li>



<li>Serina Therapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ser-stock-quote/">SER</a>) stock is increasing more than 28% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318207540&amp;type=PDF&amp;symbol=SER&amp;cdn=5bb39acd5530c99bf9d9f33aff01c374&amp;companyName=Serina+Therapeutics+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-01">merger agreement update</a>.</li>



<li>Trio Petroleum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tpet-stock-quote/">TPET</a>) shares are rising over 20% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318207241&amp;type=PDF&amp;symbol=TPET&amp;cdn=d4589c47a98244a54b35ccc5e07d6637&amp;companyName=Trio+Petroleum+Corp.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-01">borrowing money from its CEO</a>.</li>



<li>Zapata Computing (NASDAQ:<a href="https://investorplace.com/stock-quotes/zpta-stock-quote/">ZPTA</a>) stock is climbing more than 19% after its <a href="https://investorplace.com/2024/04/zpta-stock-7-things-to-know-as-zapata-computing-starts-trading-today/">recent public debut</a>.</li>



<li>CareMax (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmax-stock-quote/">CMAX</a>) shares are heading over 18% higher without any clear news this morning.</li>



<li>HWH International (NASDAQ:<a href="https://investorplace.com/stock-quotes/hwh-stock-quote/">HWH</a>) stock is jumping more than 17% this morning.</li>



<li>VirTra (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtsi-stock-quote/">VTSI</a>) shares are up over 16% on <a href="https://www.marketwatch.com/story/virtra-stock-jumps-17-after-4q-results-get-a-lift-from-streamlined-operations-36fa5579">strong Q4 earnings</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Acorda Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/acor-stock-quote/">ACOR</a>) stock is plummeting more than 59% on a <a href="https://www.nasdaq.com/press-release/acorda-therapeutics-and-merz-announce-signing-of-stalking-horse-asset-purchase">stalking horse asset purchase agreement</a>.</li>



<li>Gritstone Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/grts-stock-quote/">GRTS</a>) shares are diving over 32% after <a href="https://www.nasdaq.com/press-release/gritstone-bio-announces-pricing-of-%2432.5-million-underwritten-public-offering-2024-04">pricing a public offering</a>.</li>



<li>Canoo (NASDAQ:<a href="https://investorplace.com/stock-quotes/goev-stock-quote/">GOEV</a>) stock is tumbling more than 24% with its <a href="https://finance.yahoo.com/news/canoo-inc-goev-reports-fiscal-221142649.html">latest earnings results</a>.</li>



<li>Microvast (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvst-stock-quote/">MVST</a>) shares are taking an over 22% beating <a href="https://www.benzinga.com/news/earnings/24/04/38035918/microvast-q4-earnings-revenue-beat-eps-beat-gross-margin-improvement-and-more">despite beating Q4 estimates</a>.</li>



<li>PVH (NYSE:<a href="https://investorplace.com/stock-quotes/pvh-stock-quote/">PVH</a>) stock is dropping more than 22% after <a href="https://finance.yahoo.com/news/calvin-klein-owner-pvh-tumbles-214551310.html">warning of weakness in Europe</a>.</li>



<li>Avalo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/avtx-stock-quote/">AVTX</a>) shares are sliding close to 20% following its <a href="https://invezz.com/news/2024/04/01/avalo-therapeutics-avtx-stock-slips-after-earnings-buy-the-dip/">latest earnings report</a>.</li>



<li>GE Aerospace (NYSE:<a href="https://investorplace.com/stock-quotes/ge-stock-quote/">GE</a>) stock is decreasing over 19% <a href="https://www.marketwatch.com/story/ge-spins-off-ge-vernova-pivots-to-pure-play-aerospace-stock-58767b54">following its Vernova spinoff</a>.</li>



<li>IM Cannabis (NASDAQ:<a href="https://investorplace.com/stock-quotes/imcc-stock-quote/">IMCC</a>) shares are falling more than 18% on an <a href="https://www.nasdaq.com/press-release/imc-applauds-the-april-1st-implementation-of-the-new-israeli-cannabis-regulation">update to Israel&rsquo;s cannabis regulations</a>.</li>



<li>Aclarion (NASDAQ:<a href="https://investorplace.com/stock-quotes/acon-stock-quote/">ACON</a>) stock is slipping over 17% on Tuesday morning.</li>



<li>Pioneer Power Solutions (NASDAQ:<a href="https://investorplace.com/stock-quotes/ppsi-stock-quote/">PPSI</a>) shares close out our pre-market stock movers down more than 16% with its <a href="https://www.nasdaq.com/press-release/pioneer-achieves-51-year-over-year-increase-in-revenue-reaching-%2440.8-million-2024-04">most recent earnings report</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-april-2nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

HUT, CXAI and BDRX among pre-market losers

SOL, MESO and ACOR among pre-market losers

After some recent losses, markets turned up during Wednesday's after-hours trading session. This upturn coincided with Federal Reserve Chair Jay Po...

Oppenheimer Predicts Over 100% Rally for These 2 Healthcare Stocks

AKBA

ANGH

ANGO

ARBK

BCAN

BDRX

BIOR

CERO

CMAX

CURV

CZOO

DOMA

DTST

ENVB

GRDI

GXAI

IBIO

IINN

IMNN

ITRM

JAGX

KYCH

LIXT

MCAF

MCAFR

MDAI

MDIA

MESO

MLKN

NDRA

NTRB

NVVE

OCEA

OCGN

PEGR

PMEC

SINT

STKH

UCAR

UGRO

VEEE

VINC

VSTE

VVOS

WETG

XTKG

BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics

Opinion

Press Releases

Thinking about buying stock in American Lithium, Avalo Therapeutics, Seelos Therapeutics, Rivian Automotive, or Immunovant?

Catheter Precision Inc. (NYSE American: VTAK) Nasdaq/NYSE Stocks Ignite Multiple Buzzers (AVTX, SPCB, INTZ)

Contracts

Avalo Completes Divestiture of AVTX-800 Series

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Financing

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Avalo Reports 2023 Financial Results and Provides Business Updates

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

AMLI

HRZN

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Avalo Therapeutics Stock (NASDAQ:AVTX), Short Interest Report

People Also Watch